3 Stocks Underperforming Today In The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 77 points (0.5%) at 17,053 as of Thursday, July 3, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,714 issues advancing vs. 1,323 declining with 126 unchanged.

The Health Care sector currently sits up 0.2% versus the S&P 500, which is up 0.5%. A company within the sector that fell today was HCA Holdings ( HCA), up 0.5%. Top gainers within the sector include Thermo Fisher Scientific ( TMO), up 1.6%, Illumina ( ILMN), up 1.4%, Medtronic ( MDT), up 0.8%, Gilead ( GILD), up 1.0% and Teva Pharmaceutical Industries ( TEVA), up 0.9%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Medivation ( MDVN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Medivation is down $0.89 (-1.1%) to $77.30 on average volume. Thus far, 641,926 shares of Medivation exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $75.75-$78.36 after having opened the day at $78.34 as compared to the previous trading day's close of $78.19.

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Medivation has a market cap of $6.0 billion and is part of the drugs industry. Shares are up 22.5% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Medivation a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Medivation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors